Table 3.
Exacerbation Events in the 12-Month Post-Index Observation Period
| Overall n (%) |
ICS n (%) |
LAMA n (%) |
ICS/LABA n (%) |
LAMA/LABA n (%) |
MITT n (%) |
|
|---|---|---|---|---|---|---|
| Overall population | 8282 (100) | 558 (6.7) | 1299 (15.7) | 2588 (31.3) | 105 (1.3) | 3475 (42.0) |
| Exacerbation events (moderate or severe)a | ||||||
| 0 | 4299 (51.9) | 388 (69.5) | 888 (68.4) | 1460 (56.4) | 65 (61.9) | 1332 (38.3) |
| 1 | 1839 (22.2) | 109 (19.5) | 256 (19.7) | 594 (23.0) | 28 (26.7) | 796 (22.9) |
| ≥2 | 2144 (25.9) | 61 (10.9) | 155 (11.9) | 534 (20.6) | 12 (11.4) | 1347 (38.8) |
| Any exacerbation | 3983 (48.1) | 170 (30.5) | 411 (31.6) | 1128 (43.6) | 40 (38.1) | 2143 (61.7) |
| Rate of moderate or severe exacerbation (95% CI) | 1.01 (0.99, 1.03) |
0.61 (0.57, 0.66) |
0.80 (0.77, 0.84) |
0.94 (0.91, 0.97) |
0.80 (0.69, 0.93) |
1.44 (1.40, 1.49) |
| ≥2 moderate or ≥1 severe exacerbation | 2313 (27.9) | 66 (11.8) | 174 (13.4) | 579 (22.4) | 14 (13.3) | 1437 (41.4) |
| Severe exacerbationb | 652 (7.9) | 16 (2.9) | 44 (3.4) | 131 (5.1) | 4 (3.8) | 442 (12.7) |
| Rate of severe exacerbation (95% CI) | 0.12 (0.11, 0.12) |
0.05 (0.04, 0.06) |
0.09 (0.08, 0.10) |
0.10 (0.09, 0.11) |
0.09 (0.06, 0.13) |
0.18 (0.17, 0.20) |
Notes: aAll variables were measured in the 12 months after initiation of inhaled maintenance therapy (index date). bSevere exacerbation event is defined by an exacerbation resulting in hospitalization.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MITT, multiple-inhaler triple therapy.